Showing results (71-80 of 95) with videos related to
Sort By:
Pageof 10
Blood Advances|April 14, 2019
Preclinical development of CD37CAR T-cell therapy for treatment of B-cell lymphomaHakan Köksal, Pierre Dillard, Sarah E Josefsson, et al.Blood Advances|May 22, 2025
Circulating Tumor DNA Determinants of Response and Outcome in Relapsed/Refractory Mantle Cell LymphomaLeo Meriranta, Rasmus Rask Kragh Jørgensen, Annika Pasanen, et al.Blood Advances|December 19, 2023
MRD-driven treatment with venetoclax-R2 in mantle cell lymphoma: the Nordic Lymphoma Group MCL7 VALERIA trialMats Jerkeman, Arne Kolstad, Martin Hutchings, et al.Blood Advances|September 3, 2020
Phase 1/2a study of 177Lu-lilotomab satetraxetan in relapsed/refractory indolent non-Hodgkin lymphomaArne Kolstad, Tim Illidge, Nils Bolstad, et al.Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|August 5, 2009
Pre-emptive treatment with rituximab of molecular relapse after autologous stem cell transplantation in mantle cell lymphomaNiels S Andersen, Lone B Pedersen, Anna Laurell, et al.Med (New York, N.Y.)|May 19, 2022
A Systemic Protein Deviation Score Linked to PD-1+ CD8+ T Cell Expansion That Predicts Overall Survival in Diffuse Large B Cell LymphomaEivind Heggernes Ask, Astrid Tschan-Plessl, Thea Johanne Gjerdingen, et al.Blood|December 25, 2009
The Mantle Cell Lymphoma International Prognostic Index (MIPI) is superior to the International Prognostic Index (IPI) in predicting survival following intensive first-line immunochemotherapy and autologous stem cell transplantation (ASCT)Christian H Geisler, Arne Kolstad, Anna Laurell, et al.Blood|August 19, 2017
TP53 mutations identify younger mantle cell lymphoma patients who do not benefit from intensive chemoimmunotherapyChristian W Eskelund, Christina Dahl, Jakob W Hansen, et al.Blood|March 5, 2015
miR-18b overexpression identifies mantle cell lymphoma patients with poor outcome and improves the MIPI-B prognosticatorSimon Husby, Ulrik Ralfkiaer, Christian Garde, et al.British Journal of Haematology|May 30, 2012
Nordic MCL2 trial update: six-year follow-up after intensive immunochemotherapy for untreated mantle cell lymphoma followed by BEAM or BEAC + autologous stem-cell support: still very long survival but late relapses do occurChristian H Geisler, Arne Kolstad, Anna Laurell, et al.Pageof 10